|
시장보고서
상품코드
2076173
원발성 담관성 간경변 치료제 시장 : 약제 클래스별, 투여 경로별, 유통 채널별, 지역별Primary Biliary Cirrhosis Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
원발성 담관성 간경변 치료제 시장은 2026년에 14억 4,000만 달러로 추정되고 있으며, 2033년까지 22억 3,000만 달러에 달할 것으로 전망되고 있습니다. 2026-2033년에는 CAGR 6.5%로 성장할 것으로 예측됩니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 14억 4,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 6.50% | 2033년 시장 규모 예측 : | 22억 3,000만 달러 |
전 세계 원발성 담즙성 간경변 치료제 시장은 우르소데옥시콜산, 오베티콜산, 피브레이트 계열 약물 등 광범위한 약물 분류군을 아우르며, 경구 투여 및 비경구 투여 등의 용도로 사용되고 있습니다. 수요는 병원 약국 및 소매 약국에서의 도입과, 보다 효율적이고 신뢰할 수 있는 솔루션에 대한 요구에 힘입어 증가하고 있습니다. 지속적인 기술 발전과 최종사용자의 요구 증가가 이 시장의 성장을 주도하고 있습니다.
시장 역학 :
경구제 및 주사제의 사용 확대, 최종사용자의 수요 증가, 그리고 효율성과 성능 향상에 대한 지속적인 노력이 전 세계 원발성 담즙성 간경변 치료제 시장의 성장을 촉진할 것으로 예상되는 주요 요인입니다. 이용 가능한 선택의 폭이 넓어짐에 따라 더 다양한 사용자층이 이러한 솔루션을 이용할 수 있게 되었습니다.
예를 들어 각 기업은 병원 약국이나 소매 약국의 변화하는 수요에 대응하기 위해 제품 포트폴리오를 확대하고 있습니다. 또한 혁신 및 신기술 통합에 대한 투자 확대에 힘입어, 예측 기간 중 시장 참여자들에게 새로운 성장 기회가 창출될 것으로 전망됩니다.
본 조사의 주요 특징 :
- 이 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 이 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 전 세계 원발성 담즙성 간경변 치료제 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 원발성 담관성 간경변 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 원발성 담즙성 간경변 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 원발성 담관성 간경변 치료제 시장 : 약제 클래스별, 2026-2033년
제5장 원발성 담관성 간경변 치료제 시장 : 투여 경로별, 2026-2033년
제6장 원발성 담관성 간경변 치료제 시장 : 유통 채널별, 2026-2033년
제7장 원발성 담관성 간경변 치료제 시장 : 지역별, 2026-2033년
제1장 경쟁 구도
제2장 섹션
KSA 26.07.09Primary Biliary Cirrhosis Drugs Market is estimated to be valued at USD 1.44 billion in 2026 and is expected to reach USD 2.23 billion by 2033, growing at a compound annual growth rate (CAGR) of 6.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1.44 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.50% | 2033 Value Projection: | USD 2.23 billion |
The global primary biliary cirrhosis drugs market covers a broad set of drug class categories, including Ursodeoxycholic Acid, Obeticholic Acid, and Fibrates, used across applications such as Oral, and Parenteral. Demand is supported by adoption among Hospital Pharmacies, and Retail Pharmacies and the need for more efficient, reliable solutions. Continued technological advancement and rising end-user requirements are shaping the growth of this market.
Market Dynamics:
Growing adoption across Oral, and Parenteral, rising end-user demand, and a continued focus on improving efficiency and performance are major factors expected to drive growth of the global primary biliary cirrhosis drugs market. A wider range of available options is making these solutions accessible to a broader base of users.
For instance, companies are expanding their portfolios to address evolving requirements across Hospital Pharmacies, and Retail Pharmacies. Moreover, increasing investment in innovation and new technology integration is expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global primary biliary cirrhosis drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Ltd., Intercept Pharmaceuticals Inc., Gilead Sciences, Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Merck & Co, Inc., Mitsubishi Tanabe Pharma Corporation, Cipla Ltd., Sun Pharmaceutical Industries Ltd., and Dr. Reddys Laboratories Ltd, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global primary biliary cirrhosis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary biliary cirrhosis drugs market.
Detailed Segmentation:
- Global Primary Biliary Cirrhosis Drugs Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
- Ursodeoxycholic Acid
- Obeticholic Acid
- Fibrates
- Immunosuppressants
- Others
- Global Primary Biliary Cirrhosis Drugs Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Others
- Global Primary Biliary Cirrhosis Drugs Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- AbbVie Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Takeda Pharmaceutical Company Ltd.
- Intercept Pharmaceuticals Inc.
- Gilead Sciences, Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Merck & Co, Inc.
- Mitsubishi Tanabe Pharma Corporation
- Cipla Ltd.
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddys Laboratories Ltd
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Primary Biliary Cirrhosis Drugs Market By Drug Class, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Ursodeoxycholic Acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Obeticholic Acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Fibrates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Immunosuppressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Primary Biliary Cirrhosis Drugs Market By Route of Administration, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Parentral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Primary Biliary Cirrhosis Drugs Market By Distribution Channel, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Primary Biliary Cirrhosis Drugs Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
1. Competitive Landscape
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Takeda Pharmaceutical Company Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Intercept Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mitsubishi Tanabe Pharma Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cipla Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
2. Section
- Research Methodology
- About Us
